New combination treatment offers hope for older patients with mantle cell lymphoma

The phase 2 trial PrE0405 met its primary endpoint, achieving a complete response (CR) rate of 85% in 33 patients over the age of 60 with mantle cell lymphoma (MCL) who received bendamustine and rituximab, a standard chemo-immunotherapy treatment, along with venetoclax, which is investigational in this setting.

Related Keywords

San Diego ,California ,United States ,American ,Craiga Portell , ,Genentech ,University Of Virginia Comprehensive Cancer Center ,American Society Of Hematology ,Member Of The Roche Group ,American Society ,Virginia Comprehensive Cancer ,Federal Record ,Cell ,Immunotherapy ,Lymphoma ,Mantle Cell Lymphoma ,One ,Bone Marrow ,Dancer ,Hematology ,Hodgkin Lymphoma ,Non Hodgkin Lymphoma ,Protein ,Research ,Ituximab ,Spleen ,